Zacks Investment Research has recently initiated coverage of Lulu’s Fashion Lounge Holdings, Inc. (LVLU) with a Neutral recommendation, reflecting a balanced view of the company’s expanding wholesale opportunity and improving cost structure against ongoing financial and demand-related challenges.Lulus is a digitally native, attainable luxury fashion brand serving Millennial and Gen Z women, best known for its modern occasionwear and data-driven merchandising model. Founded in 1996 and headquartered in Chico ...

Key Takeaways Rigetti is scaling toward 1,000 qubits by 2027 using modular chiplet architecture.RGTI's 36-qubit chiplets show nearly 99.5% two-qubit gate fidelity, targeting ~150 qubits in 2026.Rigetti shares gained 12.5% in six months, while 2026 earnings estimates signal 74.3% growth.Rigetti Computing’s (RGTI) push toward a 1,000-plus qubit machine by 2027 is now grounded in its chiplet-driven design strategy, not just incremental R&D progress. During its third-quarter earnings discussion, management emph ...

Key Takeaways RingCentral reported Q4 non-GAAP EPS of $1.18, up 20.4% Y/Y, on $644M in revenue. RNG subscription revenue rose 5.5% to $622.2M, while ARR grew 7% to $2.67B. RingCentral guided 2026 revenue growth of 4%-5% and operating margin of 23%-23.5%. RingCentral (RNG) reported fourth-quarter 2025 non-GAAP earnings of $1.18 per share, surpassing the Zacks Consensus Estimate by 3.69% and increasing 20.4% year over year.Total revenues of $644 million beat the consensus mark by 0.27% and increased 4.8% year ...

Key Takeaways Ironwood expects 2026 revenues of $450-$475M, up 54% Y/Y at midpoint, on high Linzess demand.Ironwood is advancing apraglutide toward a phase III study in 1H26 following an FDA meeting.BHC guided 2026 revenues of $10.625-$10.875B, with $5.375-$5.475B from Bausch plus Lomb.Ironwood Pharmaceuticals (IRWD) and Bausch Health (BHC) operate in the branded gastrointestinal (GI) drug market, with a focus on treatments for irritable bowel syndrome (IBS) and other therapeutic areas.While Ironwood is a s ...

Shares of Elite Pharmaceuticals, Inc. (ELTP) have lost 10.7% since the company reported its earnings for the quarter ended Dec. 31, 2025. This compares with the S&P 500 Index’s 0.2% gain over the same time frame. Over the past month, the stock plunged 16.3%, underperforming the broader market, as the S&P 500 fell 0.8% during that period.ELTP’s Earnings and Revenue PerformanceFor the third quarter of fiscal 2026, Elite Pharmaceuticals reported total revenues of $31.6 million, up 119.9% from $14.4 million in ...

Core Insights - The FTSE 100 has shown strong performance in 2026, rising 7.69% year-to-date and 22.75% over the past year, outperforming the S&P 500, which is down 0.24% year-to-date but up 12.16% over the past year [1][10] Market Trends - Rising geopolitical tensions and U.S. market volatility related to AI concerns have led investors to reassess their U.S. exposure and shift away from American securities [2][3] - The "AI scare" has heightened investor anxiety, particularly affecting the S&P 500 due to its heavy concentration in the information technology sector, prompting a rotation away from U.S. equities [3] Sector Performance - The FTSE 100 benefits from a heavier weighting in banks and mining stocks, with limited exposure to big tech and AI-driven companies, contributing to its outperformance compared to the S&P 500 [4] - U.K. large caps are trading at approximately a 40% valuation discount relative to U.S. equities, with U.K. banks showing compelling valuations compared to U.S. peers [5] Economic Indicators - The S&P Global U.K. Composite PMI rose to 53.9 in February, indicating continued economic momentum, marking the strongest level since April 2024 [6] - U.K. retail sales saw a 4.5% year-over-year increase in January, the strongest annual gain in almost four years [7] - The U.K. recorded a £30.4 billion ($40.9 billion) budget surplus in January 2026, a significant improvement from the previous year [8] Inflation and Monetary Policy - U.K. inflation eased to 3.0% in January, the lowest since March 2025, raising expectations for a potential interest rate cut by the Bank of England [9][10] - Following the inflation data, market expectations for a March rate cut by the Bank of England increased to nearly 90% [10][11] Investment Opportunities - Investors can consider U.K. ETFs such as iShares MSCI United Kingdom ETF (EWU) and Franklin FTSE United Kingdom ETF (FLGB) for increased exposure to the U.K. market [12] - Other diversified ETFs with significant U.K. exposure include iShares MSCI Europe Small-Cap ETF (IEUS) and iShares Core MSCI Europe ETF (IEUR) [13]

Key Takeaways Hims & Hers expanded into menopause, perimenopause and low testosterone care with tailored plans.HIMS launched Labs and a multi-cancer blood test screening for more than 50 cancer types.Hims & Hers' investments in AI, diagnostics and global expansion aim to build a connected care platform.The renowned health and wellness platform, Hims & Hers Health, Inc. (HIMS) , has positioned itself as a leading digital health and wellness platform built around expanding access to personalized, technology-e ...

Key Takeaways AstraZeneca posted 8% revenue and 11% core EPS growth in 2025, led by 16 blockbusters.AZN guides mid-to-high single-digit 2026 revenue growth and targets $80B sales by 2030.Pfizer faces COVID declines and a 2026 LOE hit, with sales and EPS seen falling next year.Pfizer (PFE) and AstraZeneca (AZN) are two global pharmaceutical leaders with a commanding presence in oncology. For Pfizer, oncology is a key growth driver, accounting for roughly 27% of total company revenues. Beyond cancer therapies ...

An updated edition of the Jan. 6, 2026, article.Genomics is the comprehensive study of genomes—the complete set of deoxyribonucleic acid (DNA) within an organism. Rapid scientific progress in this field has intensified interest among pharmaceutical and biotechnology companies seeking deeper insight into disease biology and more effective therapeutic strategies.It is important to distinguish between genetics and genomics. Genetics focuses on individual genes and their functions, whereas genomics primarily ai ...

Key Takeaways OPEN reported a narrower Q4 adjusted loss and earnings increased YoY.Revenues beat estimates despite a year-over-year decline in home sales activity.Opendoor highlighted improving unit economics and stronger trends in newer acquisition cohorts.Opendoor Technologies Inc. (OPEN) reported fourth-quarter 2025 results, with adjusted earnings and revenues surpassing the Zacks Consensus Estimate. On a year-over-year basis, the top line decreased, but the bottom line improved.The quarterly performance ...